NASDAQ:KMPH

Zevra Therapeutics - KMPH Stock Forecast, Price & News

Add

Compare

Today's Range: N/A
50-Day Range: $4.12
▼
$6.27
52-Week Range: N/A

Volume: 64,100 shs
Average Volume: 189,500 shs
Market Capitalization: $200.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.25

Institutional Ownership

Zevra Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: ∞ Upside
$17.25 Price Target
Short Interest: Healthy
4.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$55,369 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.65) to ($0.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

414th out of 986 stocks

Pharmaceutical Preparations Industry

193rd out of 477 stocks

3.5

Analyst's Opinion

Consensus Rating
Zevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.25, Zevra Therapeutics has a forecasted upside of ∞ from its current price of $0.00.
Amount of Analyst Coverage
Zevra Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.38% of the float of Zevra Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Zevra Therapeutics has a short interest ratio ("days to cover") of 6.5.
Change versus previous month
Short interest in Zevra Therapeutics has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Zevra Therapeutics does not currently pay a dividend.
Dividend Growth
Zevra Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KMPH.

2.5

News and Social Media Coverage

News Sentiment
Zevra Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for KMPH on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zevra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,369.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.10% of the stock of Zevra Therapeutics is held by insiders.
Percentage Held by Institutions
Only 19.39% of the stock of Zevra Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Zevra Therapeutics are expected to decrease in the coming year, from ($0.65) to ($0.68) per share.

See Top Rated MarketRank™ Stocks Here

About Zevra Therapeutics (NASDAQ:KMPH) Stock

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

March 19, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Zevra Therapeutics (NASDAQ:KMPH)

March 17, 2023 | finance.yahoo.com

Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative

March 23, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 15, 2023 | finance.yahoo.com

Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

March 7, 2023 | finance.yahoo.com

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

March 6, 2023 | finance.yahoo.com

Zevra Therapeutics to Present at 35th Annual Roth Conference

March 1, 2023 | finance.yahoo.com

Zevra Therapeutics Begins Trading as ZVRA

February 28, 2023 | finance.yahoo.com

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

March 23, 2023 | Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

February 27, 2023 | finance.yahoo.com

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

February 27, 2023 | finance.yahoo.com

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

February 24, 2023 | finance.yahoo.com

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

February 23, 2023 | finance.yahoo.com

Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

February 22, 2023 | finance.yahoo.com

KemPharm Announces Corporate Name Change to Zevra Therapeutics

February 9, 2023 | finance.yahoo.com

Breakeven On The Horizon For KemPharm, Inc. (NASDAQ:KMPH)

February 5, 2023 | seekingalpha.com

KemPharm: Now A Rare Disease Play, Upgrading To A Buy Rating

February 3, 2023 | bizjournals.com

Meet KemPharm’s new CEO, a West Point grad who will lead the expansion into rare disease drugs

January 31, 2023 | finance.yahoo.com

KemPharm Enhances Senior Management Team

January 18, 2023 | finance.yahoo.com

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

January 11, 2023 | finance.yahoo.com

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

January 9, 2023 | finance.yahoo.com

KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

December 24, 2022 | reuters.com

KMPH.PH - KemPharm Inc | Stock Price & Latest News | Reuters

December 21, 2022 | finance.yahoo.com

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

November 29, 2022 | finance.yahoo.com

KemPharm Announces Appointment of Christopher Posner as New Independent Director

November 20, 2022 | finance.yahoo.com

Analysts Have Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue Estimates By 11%

November 18, 2022 | finance.yahoo.com

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

November 16, 2022 | finance.yahoo.com

KemPharm Third Quarter 2022 Earnings: Misses Expectations

See More Headlines

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Company Calendar

Last Earnings: 3/30/2022
Today: 3/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KMPH
CUSIP: N/A
CIK: 1434647
Web: www.kempharm.com
Phone: (321) 939-3416
Fax: 319-665-2577
Employees: 22
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.25
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $10.00
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,560,000.00
Net Margins: -328.56%
Pretax Margin: -335.26%
Return on Equity: -16.12%
Return on Assets: -14.17%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 10.10
Quick Ratio: 10.10

Sales & Book Value

Annual Sales: $10.72 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 23.28
Book Value: $3.63 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 34,505,000
Free Float: 34,125,000
Market Cap: $200.47 million
Optionable: Optionable
Beta: 2.16

Key Executives

Richard W. Pascoe
Chief Executive Officer & Director

Travis C. Mickle
President & Director

R. LaDuane Clifton
Chief Financial Officer, Secretary & Treasurer

Sven Guenther
Chief Scientific Officer

Daniel Gallo
Senior Vice President-Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KMPH Stock - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KMPH shares.
View KMPH analyst ratings or view top-rated stocks.
What is Zevra Therapeutics' stock price forecast for 2023?: 4 analysts have issued 1 year price objectives for Zevra Therapeutics' shares. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they predict the company's stock price to reach $17.25 in the next year.
View analysts price targets for KMPH or view top-rated stocks among Wall Street analysts.
How were Zevra Therapeutics' earnings last quarter?: Zevra Therapeutics, Inc. (NASDAQ:KMPH) announced its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.
What ETF holds Zevra Therapeutics' stock ?: iShares Neuroscience and Healthcare ETF holds 4,480 shares of KMPH stock, representing 0.37% of its portfolio.
What other stocks do shareholders of Zevra Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), DURECT (DRRX) and Paratek Pharmaceuticals (PRTK).

When did Zevra Therapeutics IPO?: (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
What is Zevra Therapeutics' stock symbol?: Zevra Therapeutics trades on the NASDAQ under the ticker symbol "KMPH."
Who are Zevra Therapeutics' major shareholders?: Zevra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (1.43%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.90%), Retirement Planning Co of New England Inc. (0.86%), Susquehanna International Group LLP (0.00%) and Mystic Asset Management Inc. (0.51%). Insiders that own company stock include David S Tierney, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Tamara A Seymour and Travis C Mickle.
View institutional ownership trends.
How do I buy shares of Zevra Therapeutics?: Shares of KMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
How much money does Zevra Therapeutics make?: Zevra Therapeutics (NASDAQ:KMPH) has a market capitalization of $0.00 and generates $10.72 million in revenue each year.
How can I contact Zevra Therapeutics?: Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:KMPH) was last updated on 3/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zevra Therapeutics - KMPH Stock Forecast, Price & News

Zevra Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zevra Therapeutics (NASDAQ:KMPH) Stock

KMPH Stock News Headlines

KMPH Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KMPH Stock - Frequently Asked Questions

Overall MarketRank^™